E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Type I gastric carcinoids, chronic atrophic gastritis and hypergastrinaemia. |
|
E.1.1.1 | Medical condition in easily understood language |
These patients make antibodies that damage the stomach. This leads to a high level of gastrin, which makes certain cells in the stomach grow and, with time, turn into tumours (gastric carcinoids). |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10060377 |
E.1.2 | Term | Hypergastrinaemia |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003685 |
E.1.2 | Term | Atrophic gastritis |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10017769 |
E.1.2 | Term | Gastric carcinoid |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To find out if YF476 is an effective medical treatment for type I gastric carcinoids.
|
|
E.2.2 | Secondary objectives of the trial |
To find out if YF476 has any important side effects in patients with type I gastric carcinoids.
To find out if YF476 affects biomarkers of ECL cell activity. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
We include patients who meet the following criteria.
*Patients known to have gastric carcinoids associated with chronic atrophic gastritis and hypergastrinaemia, and who attend the out-patient clinic of the investigators;
*Men, post-menopausal women, pre-menopausal women who have been sterilised by tubal ligation, hysterectomy or bilateral oophrectomy, or pre-menopausal women using reliable contraception: condom and spermicide or intra-uterine device;
*Adults ≥ 18 years;
*Good general health; and
*Able to give fully-informed, written consent. |
|
E.4 | Principal exclusion criteria |
We exclude participants who meet the following criteria:
*Women who are pregnant, lactating or using a steroid contraceptive;
*History of gastric surgery, apart from surgery for gastric carcinoids;
*Evidence of Zollinger-Ellison syndrome;
*Prolonged QTc interval (>450 msec);
*Certain medicines and herbal remedies taken during the 7 days before Visit 1 (see protocol);
*Previous treatment with somatostatin; or
*Participation in other clinical trials of unlicensed medicines within the previous 3 months.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Visual assessment of the number, size and distribution of gastric carcinoids.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Visual assessment of the number, size and distribution of gastric carcinoids is carried out at 6 and 12 weeks after starting the initial 12 weeks' treatment; and at 24 and 52 weeks after starting the extended dosing period. |
|
E.5.2 | Secondary end point(s) |
Effect of YF476 on biomarkers.
Safety and tolerability of long-term treatment with YF476. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Biomarker assessments after 3, 6, 9, and 12 weeks after starting the initial 12 weeks' treatment; and 12, 24, 36, and 52 weeks after starting the extended dosing period.
Assessment of adverse events and safety tests of blood and urine after 3, 6, 9, and 12 weeks after starting the initial 12 weeks' treatment; and 12, 24, 36, and 52 weeks after starting the extended dosing period. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will end when the last subject has had their last visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |